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Rationale: Rifabutin was recommended in place of rifampin during
treatment of HIV-related tuberculosis (TB) to facilitate concomitant
potent antiretroviral therapy, but this approach has not been evalu-
ated in a prospective study.
Objective: To evaluate the activity of intermittent rifabutin-based
therapy.
Methods: Patients with culture-confirmed TB were treated under
direct supervision with 2 mo of rifabutin, isoniazid, pyrazinamide,
and ethambutol (given daily, thrice-weekly, or twice-weekly per the
local tuberculosis control program), followed by 4 mo of twice-
weekly rifabutin plus isoniazid.
Measurements: Culture-positive treatment failure or relapse.
Main Results: A total of 169 eligible patients were enrolled. Most
had advanced HIV disease; the median CD4 cell count and HIV-
RNA level were 90 cells/mm3 (interquartile range, 35–175) and 5.3
log10 copies/ml (interquartile range, 4.8–5.7), respectively. Nine
(5.3%) patients had culture-positive treatment failure (n  3) or
relapse (n  6). Eight of these nine (89%) cases had isolates with
acquired rifamycin resistance. Treatment failure or relapsewas asso-
ciated with baseline CD4 lymphocyte count, being 12.3% (9/73;
95% confidence interval, 6.5–22.0%) among patients with CD4 
100 cells/mm3 versus 0% (0/65; 95% confidence interval, 0.0–4.5%)
among those with higher CD4 lymphocyte counts (p  0.01). One
hundred thirty-seven (81%)patients received antiretroviral therapy
during TB treatment. Adverse events were common, but only two
patients (1%) permanently discontinued study drugs.
Conclusions: Intermittent rifabutin-based therapy forHIV-related TB
was well tolerated, but there was a high risk of treatment failure
or relapse with acquired rifamycin resistance among patients with
low CD4 lymphocyte counts.
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In many parts of the world, tuberculosis (TB) is the most com-
mon opportunistic infection among persons with HIV disease
(1–3). TB complicating HIV infection is associated with a 20 to
50% risk of death within the first year after diagnosis (4–6).
Death soon after the diagnosis may be due to TB, but most
deaths among patients with HIV-related TB are due to other
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complications of HIV (4, 5). Antiretroviral therapy markedly
improves survival among patients with advanced HIV disease
(7, 8) and may improve survival with HIV-related TB (9). How-
ever, the use of combination antiretroviral therapy during treat-
ment of TB is complicated by overlapping side-effect profiles of
anti-TB and antiretroviral drugs, complex drug–drug interac-
tions between the rifamycins and many antiretroviral drugs, and
immune reconstitution reactions after initiation of antiretroviral
therapy (10).
Rifampin markedly decreases serum concentrations of the
HIV-1 protease inhibitors (11), and has substantial effects on
concentrations of two of the available nonnucleoside reverse-
transcriptase inhibitors (delavirdine and nevirapine) (12), thus
limiting the choice of antiretroviral drugs.An alternate rifamycin
antibiotic, rifabutin, has much less effect on serum concentra-
tions of these antiretroviral drugs (12) and appears to be as
potent as rifampin for the treatment of TB (13–15). Therefore,
rifabutin-based therapy was recommended by the Centers for
Disease Control and Prevention (CDC) as a way of avoiding
serious drug–drug interactions and allowing use of potent anti-
retroviral therapy during TB treatment (16). However, there is
relatively little published clinical experiencewith rifabutin-based
therapy for HIV-related TB (15). The Tuberculosis Trials
Consortium evaluated the efficacy and tolerability of a standard
rifabutin-based regimen for treatment of HIV-related TB
(TBTCStudy 23). Preliminary results of this study were reported
in the form of an abstract (17) and a special “Note to Readers”
of the Morbidity and Mortality Weekly Report (18).
METHODS
Patients 18 yr or older at participating sites in the United States and
Canada with confirmed HIV infection and suspected or confirmed TB
were eligible for enrollment. Patients were excluded if they had received
treatment for active or latent TB within the previous 6 mo, were preg-
nant or breast-feeding, or if the initial mycobacterial cultures were
negative or grew rifamycin-resistant Mycobacterium tuberculosis. The
study was reviewed and approved by the institutional review boards of
the CDC and each clinical site. All patients gave written, informed
consent.
Patients could be enrolled at any time during the first 2 mo of TB
treatment. Patients who enrolled before the completion of the intensive
phase of therapy (the first 2 mo) received rifabutin, isoniazid, pyrazi-
namide, and ethambutol, given daily for the first 2 wk and then either
daily (5 d/wk), thrice-weekly, or twice-weekly based on the preference
of the local TB control program. After 2 mo, all patients were treated
with rifabutin (300 mg) plus isoniazid (15 mg/kg; maximum, 900 mg)
given twice weekly. All TB treatment was given as directly observed
therapy, defined as the ingestion of studymedication under the observa-
tion of a member of the study team. Completion of study therapy was
defined as observed ingestion of 36 twice-weekly continuation-phase
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doses, not by calendar time. The type and timing of initiation of antiret-
roviral therapy were not determined by the study protocol. Rifabutin
doses were adjusted according to current guidelines if given with the
HIV-1 protease inhibitors or efavirenz (19).
TB treatment duration was 6 mo, with a mandatory extension to
9 mo for patients with a positive culture or lack of a clinical response
at 2 mo of treatment (defined as persistent fever or progressive weight
loss, and increase in size of lymph nodes, abscesses, or other tuberculous
lesions) (16). Patients having an isoniazid-resistant isolate or who were
intolerant of isoniazid were treated with 9 mo of rifabutin, pyrazinam-
ide, and ethambutol; those having a pyrazinamide-resistant isolate or
whowere intolerant of pyrazinamide were treated with 9 mo of rifabutin
plus isoniazid.
CD4 lymphocyte count and HIV-RNA level (bDNABayer Versant
3.0; Bayer Corporation, Tarrytown, NY) were performed at enrollment,
after 2mo of TB therapy, at end of treatment, and every 6mo thereafter.
We attempted to obtain sputum specimens from all patients at 2 mo
of treatment, regardless of the presence or absence of clinically evident
pulmonary involvement. Patients with pulmonary involvement had
sputum cultures obtained monthly during therapy and then at 1.5, 3,
6, 12, 18, and 24 mo after completing therapy. At all of these time
points, patients who could not produce an expectorated sputum speci-
men underwent sputum induction. Mycobacterial cultures were per-
formed using liquid plus solid media at certified local laboratories.
Isolates obtained at diagnosis and at the time of treatment failure or
relapse underwent confirmatory drug-susceptibility testing (using solid
media and the proportion method), DNA fingerprinting (20, 21), and
sequencing of the rpoB gene (22).
The primary endpoint of the study was culture-confirmed treatment
failure (positive culture during treatment, at or afterMonth 4) or relapse
(positive culture after completing treatment). The planned sample size
was 215 patients, allowing for 80% power to detect whether the rate
of treatment failure plus relapse was higher than 10%, twice that ex-
pected for treatment of drug-susceptible TB ( 5%).
Data Analysis
All patients with culture-positive TB are included in the primary analy-
sis; a second analysis was performed using patients who completed
therapy as specified in the protocol. Categoric variables were compared
using the two-tailed Fisher’s exact test or 2, and continuous variables
with the Wilcoxon two-sample test. To identify factors associated with
acquired rifamycin resistance, we compared patients having acquired
rifamycin resistance to all other patients in the study. All patients in the
study completed 8 wkof four-drug therapy, but there were differences in
the amount of that therapy that was administered twice-weekly. For
the analysis of risk factors for acquired rifamycin resistance, patients
who received four or more doses of their treatment as twice-weekly
dosing during the first 2 mo were defined as having received twice-
weekly therapy during induction phase. Because of the small number
of cases of treatment failure or relapse it was not appropriate to perform
multivariate analysis (23). However, among the 73 patients with a base-
line CD4 cell count below 100 (which included all eight patients with
acquired rifamycin resistance), we performed a stratified analysis of those
factors associatedwith acquired rifamycin resistance in univariate analysis
(p  0.20). Data analysis was performed using SAS version 8.0 (SAS
Institute, Cary, NC) and EpiInfo, version 6.04d (CDC, Atlanta, GA).
RESULTS
A total of 180 patients were enrolled between December 1998
and March 2002 (Figure 1), 11 of whom were later excluded
from the study (eight patients who did not have a positive myco-
bacterial culture and three patients who enrolled at sites that
were closed soon after study initiation). The 169 remaining pa-
tients were used for the analyses that follow. Most patients were
male and of Black or Hispanic race/ethnicity; 40% were born
outside of the United States and Canada (Table 1). Nearly 45%
of patients had extrapulmonary manifestations of TB; 22 (13%)
had only extrapulmonary involvement. Most patients had ad-
vancedHIV disease at the time of TB diagnosis; the median CD4
cell count and HIV-RNA level were 90 cells/mm3 (interquartile
Figure 1. Patient flow in the study. *One patient died after having failed;
**one patient died after having relapsed (total deaths  25).
range, 35–175) and 5.3 log10 copies/ml (interquartile range, 4.8–
5.7), respectively.
A data and safety monitoring board reviewed outcome data
three times. In March 2002, the board recommended that enroll-
ment be stopped because five cases of acquired rifamycin resistance
had occurred among patients with treatment failure or relapse. At
TABLE 1. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS
OF PATIENTS
Patients Included
Characteristic (n  169)





White, non-Hispanic 19 (11)
Native American 3 (2)
Asian/Pacific Islander 6 (4)
Country of origin, n (%)
United States or Canada 100 (59)
Other 69 (41)
Homeless the within past yr, n (%) 45 (27)
Injection drug use within the past yr, n (%) 17 (10)
Alcohol abuse within the past yr, n (%) 57 (34)
Educational level, n (%)
8th grade or less 39 (23)
9th–11th grade 48 (29)
Completed high school 47 (28)
Some college 34 (20)




Isoniazid resistance/isoniazid intolerance 3/3
Pyrazinamide resistance*/pyrazinamide intolerance 5/1
Median CD4 cell count at TB diagnosis (IQR) 90 (35–175)
Median HIV RNA (log10) at TB diagnosis (IQR) 5.3 (4.8–5.7)
Prior AIDS-defining illness, n (%) 23 (14)
Definition of abbreviations: IQR  interquartile range; TB  tuberculosis.
* Three of the five pyrazinamide-resistant isolates were identified as Mycobacte-
rium bovis.
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the time enrollment was stopped, investigators were encouraged
to use more frequent therapy (daily or thrice-weekly) and/or
add medications such as ethambutol for patients having CD4
lymphocyte counts of less than 100 cells/mm3 at study entry.
Patients were monitored for 2 yr after completing therapy.
TB Treatment
Of the 169 patients, 37 (22%) enrolled before starting TB treat-
ment, and were therefore treated with rifabutin from the outset.
The other 132 patients were enrolled during the first 2 mo of
therapy and had received a median of 33.5 d of rifampin-
containing therapy (interquartile range, 16.5–56 d). During the
first 2 mo of TB treatment, 76 (45%) of patients received twice-
weekly therapy. Most patients were treated for 6 mo. Treatment
was extended to 9 mo for 16 patients (eight patients who were
intolerant to or had an isolate resistant to isoniazid [n  5] or
pyrazinamide [n  3], four patients who had a positive sputum
culture at 2 mo of treatment, two patients with lack of clinical
response by 2 mo, and two patients because of provider prefer-
ence). Thirty of 169 (17.8%) were lost to follow-up before com-
pleting the study or reaching an endpoint (Figure 1). However,
the lost-to-follow-up rate at 12 mo after completing therapy, the
period of highest risk for recurrent TB, was 7.1% (12 of 169).
Treatment Failure and Relapse
Nine patients had culture-positive treatment failure or relapse:
three patients had treatment failure and six had relapse. Four
of the six cases of relapse occurred within 6 mo of completing
TB treatment. Overall, 5.3% (9 of 169) of patients had treatment
failure or relapse; by Kaplan-Meier analysis, 6.6% of patients
had treatment failure or relapse by 2 yr after completing therapy.
The rate of treatment failure or relapse was 3.0 per 100 patient-
years of follow-up. Among the 142 patients who completed the
study regimen as specified in the protocol, eight (5.6%) had
treatment failure or relapse (one patient with acquired rifamycin
resistance had treatment failure after nonadherence). Treatment
failure or relapse was associated with baseline CD4 lymphocyte
count, being 12.3% (9/73; 95% confidence interval, 6.5–22.0%)
among patients with CD4 counts of less than 100 cells/mm3 versus
0% (0/65; 95% confidence interval, 0.0–4.5%) among those with
higher CD4 lymphocyte counts (p  0.01).
Eight of the nine isolates (89%) obtained at the time of
treatment failure or relapse had acquired rifamycin resistance
(three cases of treatment failure and five cases of relapse). The
median time from enrollment to acquired rifamycin resistance
was 8.3 mo (range, 4.7–24.5 mo).Multidrug resistance developed
in one of these cases. A patient with an isolate having baseline
pyrazinamide resistance developed recurrent suppurative cervi-
cal adenopathy at 5 mo of directly observed therapy. A percuta-
neous aspirate yielded an isolate with acquired rifamycin and
isoniazid resistance. For all nine cases, the DNA fingerprint
patterns of paired isolates at initial diagnosis and the time of
treatment failure or relapse were identical. The rpoB gene se-
quences of the eight isolates having acquired rifamycin resistance
had mutations previously associated with rifampin resistance
(Ser531Leu [three cases], Gln513Leu [two cases], His526Tyr
[two cases], His526Asp [one case]) (22). All patients with treat-
ment failure or relapse responded to retreatment with a regimen
active against rifamycin-resistant TB.
Factors Associated with Rifamycin-resistant Treatment
Failure or Relapse
Patients with acquired rifamycin treatment failure or relapse
had lower CD4 lymphocyte counts at the time of TB diagnosis
than other patients (median CD4 lymphocyte count, 26 cells/mm3
[interquartile range, 13–39] vs. 99 cells/mm3 [interquartile range,
40–202]; p  0.001, Wilcoxon). Birth outside the United States
or Canada, the presence of extrapulmonary manifestations of
TB, twice-weekly TB treatment during the first 2 mo of TB
treatment, and lack of use of antiretroviral therapy during the
first 2 mo of TB treatment were more common among cases
with acquired rifamycin resistance (Table 2). Use of rifampin
during intensive-phase therapy was not associated with risk of
acquired rifamycin resistance. In a stratified analysis of those
patients with baseline CD4 lymphocyte count of less than
100 cells/mm3, lack of use of antiretroviral therapy during the
first 2 mo of TB treatment remained of borderline statistical
significance (Table 3; p  0.07).
Use of Antiretroviral Therapy
Thirty-eight (22%) patients were on antiretroviral therapy at the
time of TBdiagnosis, and 99 patients (59%) started antiretroviral
therapy during TB treatment. Therefore, 81% of patients (137
of 169) received antiretroviral therapy during TB treatment.
Patients not started on antiretroviral therapy during TB treat-
ment had higher CD4 lymphocyte counts than those who re-
ceived antiretroviral therapy during TB treatment (median CD4
lymphocyte count among those who did not start antiretroviral
therapy, 149 cells/mm3 [interquartile range, 73–261] vs. 79 [inter-
quartile range, 32–150]; p 0.02). All patients who were treated
with antiretroviral treatment received combination therapy; the
most common regimens were two nucleoside analogs plus nelfi-
navir (47 patients) and two nucleoside analogs plus efavirenz
(45 patients). CD4 lymphocyte counts rose substantially and
HIV-RNA levels decreased during TB treatment (Figure 2).
Twenty-six of the 169 patients (15%) were diagnosed with
immune reconstitution reactions, all of which occurred among
patients receiving antiretroviral therapy (26 of 137, 19%).
Adverse Events
Of 169 patients in the study, 25 (14.8%) died and 25 (14.8%)
developed a new AIDS-defining condition (24). None of the
deaths were due to TB; 17 were due to complications of HIV
disease (AIDS wasting, five patients; opportunistic infection,
nine patients; HIV-related malignancy, three patients), three to
illicit drug overdose, and five to other causes (suicide, cardiovas-
cular disease, liver failure, non–HIV-related cancer). Although
adverse events were common during TB treatment, few were
believed to be due to the TB treatment regimen, and only two
patients permanently stopped study drugs due to an adverse
event (Table 4).
DISCUSSION
This study is the largest prospective evaluation of a rifabutin-
based TB treatment regimen in conjunction with use of potent
antiretroviral therapy. The rate of treatment failure or relapse
observed in the study was approximately 5%, similar to that
seen with standard rifampin-based TB therapy (5, 25), demon-
strating the potency of rifabutin-based treatment for the treat-
ment of HIV-related TB. The treatment regimen was also well
tolerated, with only 1% of patients permanently discontinuing
rifabutin due to an adverse event. However, eight of the nine
patients who had treatment failure or relapse had isolates with
acquired rifamycin resistance. Because rifamycins are the key to
short-course TB treatment, the occurrence of acquired rifamycin
resistance led to the early discontinuation of the study.
One of the most important benefits of directly observed ther-
apy for TB is that it prevents selective drug taking, and thereby
almost completely prevents acquired drug resistance (14, 26,
27). However, this study demonstrates that this axiom of TB
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TABLE 2. UNIVARIATE ANALYSIS OF FACTORS ASSOCIATED WITH ACQUIRED RIFAMYCIN RESISTANCE
Patients with Patients without
Acquired Rifamycin Acquired Rifamycin
Characteristic Resistance (n  8) Resistance (n  161) p Value‡
Demographic factors
Median age, yr (IQR) 38 (33–42) 40 (34–46) 0.46
Male/female 7/1 126/35 1.00
Race/ethnicity, n (%)
Hispanic 5 (62) 52 (32) 0.39
White, non-Hispanic 1 (13) 18 (11)
Black 2 (25) 82 (51)
Native American 0 3 (2)
Asian/Pacific Islander 0 6 (4)
Born outside the United States and Canada, n (%) 6 (75) 63 (39) 0.06
Median body mass index at TB diagnosis (IQR) 19.9 (17.8–26.0) 21.2 (18.7–23.7) 0.84
Aspects of TB
Presence of initial resistance to isoniazid or pyrazinamide, n (%) 1 (13) 7 (4) 0.33
Site of TB involvement, n (%)
Pulmonary only 2 (25) 91 (56)
Any extrapulmonary 6 (75) 70 (43) 0.14
Presence of cavitation on chest radiograph, n (% of those with pulmonary involvement) 1 (20) 22 (16) 1.00
Bilateral lung involvement on chest radiograph, n (% of those with pulmonary involvement) 1 (17) 20 (15) 1.00
TB treatment
Use of twice-weekly therapy during intensive phase, n (%) 6 (75) 70 (44) 0.15
Received rifampin during intensive phase, n (%) 7 (88) 125 (78) 1.00
Sputum culture positive at 2 mo, n (% of those with pulmonary involvement) 0 5 (4) 1.00
Use of drugs during TB treatment that are known to decrease concentrations of rifabutin,* n (%) 2 (25) 48 (30) 1.00
Use of drugs during TB treatment that are known to increase concentrations of rifabutin,† n (%) 3 (38) 72 (45) 1.00
Aspects of HIV/antiretroviral therapy
Median CD4 lymphocyte count at diagnosis (IQR) 26 (13–39) 99 (40–202) 0.001
Median HIV RNA level at diagnosis (IQR) 5.6 (5.3–5.6) 5.3 (4.8–5.7) 0.40
Use of antiretroviral therapy during TB treatment, n (%) 7 (87) 130 (81) 1.00
Use of antiretroviral therapy during first 2 mo of TB treatment, n (%) 1 (14) 73 (56) 0.05
Occurrence of an immune reconstitution event, n (%) 1 (13) 25 (16) 1.00
For definition of abbreviations, see Table 1.
* Efavirenz.
† HIV-1 protease inhibitors, clarithromycin, fluconazole.
‡ p value based on Wilcoxon, 2, or Fisher’s exact test (see METHODS).
treatment is not true for patients with advanced HIV disease.
It is also notable that the drug to which resistance was acquired
in this and other studies (5, 25, 28, 29) was nearly always the
rifamycin component of the regimen (rifampin, rifabutin, or
rifapentine). Among patients with HIV-related TB treated with
directly observed therapy, there are two consistent associations
in this and previous studies with the occurrence of acquired
rifamycin resistance: the presence of severe immunodeficiency
(CD4 lymphocyte count  100 cells/mm3) and the use of once-
or twice-weekly therapy. Acquired rifamycin resistance has been
reported with twice-weekly rifabutin plus isoniazid (4.7% in the
present study) and with twice-weekly rifampin plus isoniazid
TABLE 3. STRATIFIED ANALYSIS OF FACTORS ASSOCIATED WITH ACQUIRED RIFAMYCIN
RESISTANCE AMONG PATIENTS WITH BASELINE CD4 LYMPHOCYTE
COUNT  100 CELLS/mm3 (n  73)
Patients with Patients without
Acquired Rifamycin Acquired Rifamycin
Characteristic Resistance (n  8 ) Resistance (n  65) p Value*
Born outside the United States and Canada, n (%) 6 (75) 29 (45) 0.14
Any extrapulmonary site of TB involvement, n (%) 6 (75) 34 (52) 0.28
Use of twice-weekly therapy during intensive phase, n (%) 6 (75) 28 (43) 0.13
Use of antiretroviral therapy during first 2 mo of TB treatment, n (%) 1 (13) 32 (49) 0.07
Definition of abbreviation: TB  tuberculosis.
* Fisher’s exact test (expected values  5).
(2.0, 3.7, and 1.7%) (5, 29, 30). In contrast, the rate of acquired
rifamycin resistance among HIV-infected patients treated with
daily (5–7 d/wk) rifampin-based therapy (29, 31, 32), or rifabutin-
based therapy (29, 31) has been very low. The interpretation of
these data from different clinical trials and observational cohorts
is difficult. We conclude that there is a risk of acquired rifamycin
resistance with rifabutin or rifampin when given twice weekly,
but whether the risk is higher with one of these agents is not
clear.
In addition to the associations with severity of immunosup-
pression and dosing frequency, abnormal pharmacokinetics of
anti-TB drugs may also be a part of the pathophysiology of
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Figure 2. Changes in median HIV RNA level (log10) and CD4 cell count
(cells/l) during the 12 mo after the diagnosis of tuberculosis among
patients who did (A ) and did not (B ) receive antiretroviral therapy
during tuberculosis treatment. The median value is shown as a black
line; the grey lines indicate the 25th and 75th percentile (the interquartile
range).
acquired rifamycin resistance. Among patients in this trial who
enrolled in a pharmacokinetic substudy, patients with low con-
centrations of rifabutin were at increased risk of acquired rifamy-
cin resistance, even after adjusting for baseline CD4 cell count
TABLE 4. SELECTED ADVERSE EVENTS DURING
TUBERCULOSIS THERAPY
Event No. (% )
Serious events (Grade 4), total 55 (32.5)
Serum AST or ALT  10 times upper limit of normal (Grade 4) 13 (7.7)
Absolute neutrophil count  500 (Grade 4) 8 (4.7)
Hemoglobin
 7 g/dl (Grade 3) 6 (3.6)
5 g/dl (Grade 4) 0
Platelets  10,000 (Grade 4) 0
Arthralgia (any grade) 2 (1.2)
Skin rash (any grade) 13 (7.7)
Uveitis 0
Temporary discontinuation of study drugs due to toxicity 24 (14)
Permanent discontinuation of study drugs due to toxicity 2 (1)
Definition of abbreviations: ALT  alanine transaminases; AST  aspartate
transaminase.
and dosing frequency (33). Thus, it appears that three factors
are closely associated with acquired rifamycin resistance: severe
immunodeficiency, highly intermittent dosing, and low concen-
trations of the rifamycin component of the regimen. These asso-
ciations suggest that, in the relative absence of immune control,
low concentrations of the rifamycin near the end of the pro-
longed dosing interval allowmycobacterial replication and selec-
tion for rifamycin resistance.
The risk of acquired rifamycin resistance in our study was
lower among patients who received antiretroviral therapy during
the first 2 mo of TB treatment. The interpretation of this finding
is difficult: the study could not capture the many factors that led
to differences in the timing of antiretroviral therapy, and this
association has not been evaluated in previous studies. Although
our sample size is relatively small, these data support the hypoth-
esis that immune reconstitution is beneficial in the treatment
of HIV-associated TB. The question of the optimal timing of
antiretroviral therapy during TB treatment is complex and is
currently being evaluated in randomized clinical trials.
The TB treatment regimen in this study was chosen to deter-
mine if TB treatment could be used safely with potent antiret-
roviral therapy. In that respect, the study regimen succeeded;
most patients received and benefited from potent antiretroviral
therapy during TB therapy. Baseline characteristics of patients
in this trial were quite similar to those of patients enrolled in a
trial that was performed in many of the same study sites, before
the availability of potent antiretroviral therapy (Table 5). The
markedly lower rates of death (4.9 vs. 20.0%) and new opportu-
nistic illness during the first year after TB diagnosis in the present
study suggest that the benefits of antiretroviral therapy can be
extended to patients being treated for TB. This is an important
finding because TB is the most common opportunistic infection
in areas of the world with high rates of HIV infection, areas
in which combination antiretroviral therapy is now being in-
troduced. Rifabutin has only been approved in a relatively
small number of resource-rich countries (e.g., United States and
western Europe). This limits the direct application of our results
to many countries with high rates of HIV-related TB in which
rifampin is the only available rifamycin antibiotic. However, some
potent antiretroviral regimens (e.g., efavirenz or ritonavir with
two nucleoside analogs) can be used with rifampin-based TB
therapy (11, 34), and should allow patients to obtain the benefits
of potent antiretroviral therapy given during TB treatment.
The major limitation of this study is the lack of a randomized
comparison group. Although use of twice-weekly therapy was
associated with acquired rifamycin resistance among patients
Burman, Benator, Vernon, et al.: Rifabutin for Treatment of HIV-TB 355
TABLE 5. COMPARISON OF USE OF COMBINATION ANTIRETROVIRAL THERAPY AND RATES OF
HIV DISEASE PROGRESSION IN A TREATMENT OF HIV-RELATED TUBERCULOSIS IN THE
UNITED STATES AND CANADA IN THE ERA PRIOR TO POTENT ANTIRETROVIRAL
THERAPY VERSUS THE PRESENT STUDY
CPCRA/ACTG* Present Study
(n  101) (n  169)
Years of enrollment 1993–1995 1999–2002
Median enrollment CD4 cell count (IQR) 86 (35–230) 90 (35–175)
Use of potent antiretroviral therapy during TB treatment, n (%) 0 137 (81)
Death within 12 mo of starting TB treatment (% by Kaplan-Meier analysis) 20.0 4.9
HIV disease progression (new opportunistic infection or death) within
12 mo of starting TB treatment (% by Kaplan-Meier analysis) 38.9 15.4
Definition of abbreviations: ACTG  AIDS Clinical Trials Group; CPCRA  Community Programs for Clinical Research on AIDS;
IQR  interquartile range; TB  tuberculosis.
* Data from Reference 5.
with low baseline CD4 lymphocyte counts, our study did not
include a group randomized tomore frequent dosing. Evaluating
the relationship between dosing frequency and the success of
treatment of HIV-related TB should be a high priority for future
randomized studies. Although this is one of the largest prospec-
tive studies of treatment of HIV-related TB, the sample size
limits the power of subgroup comparisons. Finally, the substan-
tial proportion of patients lost after the first year of follow-up,
but before completing 2 yr of follow-up, is a limitation of our
study.
A largely twice-weekly rifabutin-based regimen for HIV-
related TB was associated with an unacceptable risk of acquired
rifamycin resistance. The results of this and other studies were
the basis for national recommendations that persons with CD4
lymphocyte counts of less than 100 cells/mm3 should not be
treated with twice-weekly therapy, at least during the first
2 mo of therapy (18, 35). Patients with baseline CD4 lymphocyte
counts more than 100 cells/mm3 did well in this study, but addi-
tional experience is needed to evaluate intermittent therapy in
this important subgroup. Intermittent therapy greatly facilitates
directly observed therapy, so randomized trials of dosing fre-
quency should be a high priority among patients with HIV-
related TB. Finally, our study supports the recommendation to
use antiretroviral therapy among patients with advanced HIV
disease andTB (16), as such patients can obtain dramatic benefits
from potent antiretroviral therapy.
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